Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Clinical trial NCT04332367 · RECRUITING
Trial details
- NCT number
- NCT04332367
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-01
- Primary completion
- 2026-09-30
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.